Economics & Value

Acute Myeloid Leukemia Treatment Episodes Linked to Significant Economic Burden

Chase Doyle

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Value-Based Care

Atlanta, GA—A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia and substantial economic burden. According to data presented at ASH 2017, healthcare resource use and direct healthcare costs were associated with high-intensity chemotherapy induction, hematopoietic stem-cell transplantation (HSCT), and episodes of relapsed or refractory disease in a US commercially insured population. [ Read More ]

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Chase Doyle

February 2018, Vol 9, No 1 | Payers’ Perspectives In Oncology: ASH 2017 Highlights - Value-Based Care

Atlanta, GA—A recent analysis of a commercial claims database suggests that oral therapy for multiple myeloma may help decrease the economic burden for patients and healthcare systems. According to data presented at ASH 2017, patients with multiple myeloma who received injectable therapy used significantly more disability benefits and incurred higher productivity costs than patients who received oral medications. [ Read More ]

Proactive Symptom Self-Reporting Extends Survival in Patients with Metastatic Cancer

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Value-Based Care

Chicago, IL—The use of an online tool to self-report symptoms during treatment for metastatic cancer extended survival by 5 months compared with usual care according to a study presented at ASCO 2017. In addition, online self-reporting of symptoms improved quality of life (QOL) and reduced emergency department visits and hospitalizations versus usual care. [ Read More ]

Oncologists Must Begin to Discuss Financial Toxicity with Patients

Chase Doyle

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Value-Based Care

Chicago, IL—The issues underlying financial toxicity are undoubtedly complex, but for oncologists looking to help their patients cope, simply noting the cost of treatment from the outset may be the best place to start. As the cost of cancer care continues to rise, greater transparency throughout the process of drug pricing and drug payment needs to become part of the clinical discussion, said Leonard Saltz, MD, Chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. [ Read More ]

BEACOPP Regimen Superior to ABVD in Newly Diagnosed, Advanced Hodgkin Lymphoma

Chase Doyle

February 2017, Vol 8, No 1 - Value-Based Care

San Diego, CA—In transplant-eligible patients with newly diagnosed, advanced-stage Hodgkin lymphoma, a decision-analytic model showed that chemotherapy with bleomycin, plus etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) maximized life-expectancy and quality-adjusted life expectancy compared with doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD) therapy in the first-line setting, reported Abi Vijenthira, MD, Princess Margaret Cancer Centre, University of Toronto, Canada, at the 2016 American Society of Hematology meeting. [ Read More ]

Increased Utilization of Biosimilars in Oncology Could Save Payers Millions

Chase Doyle

February 2017, Vol 8, No 1 - Economics & Value, Value-Based Care

San Diego, CA—Filgrastim (Neupogen), a short-acting granulocyte colony-stimulating factor (G-CSF), has helped to manage chemotherapy-induced neutropenia in patients with nonmyeloid malignancies, but it comes with a hefty price tag. According to a recent study, biosimilars of filgrastim may provide a more affordable option for US payers, suggested Susan Gabriel, Director of Global Health Economics and Outcomes Research, Teva Pharmaceuticals, Frazer, PA, at the 2016 American Society of Hematology meeting. [ Read More ]